These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38777187)

  • 1. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
    Silverberg JI; Eichenfield LF; Hebert AA; Simpson EL; Stein Gold L; Bissonnette R; Papp KA; Browning J; Kwong P; Korman NJ; Brown PM; Rubenstein DS; Piscitelli SC; Somerville MC; Tallman AM; Kircik L
    J Am Acad Dermatol; 2024 Sep; 91(3):457-465. PubMed ID: 38777187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
    Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
    J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
    Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
    J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
    N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
    Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
    Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety results from 2 Japanese phase 3 trials.
    Igarashi A; Tsuji G; Fukasawa S; Murata R; Yamane S
    J Dermatol; 2024 Oct; 51(10):1269-1278. PubMed ID: 39150292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
    Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
    J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
    Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
    Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial.
    Lee YW; Won CH; Jung K; Nam HJ; Choi G; Park YH; Park M; Kim B
    Br J Dermatol; 2019 May; 180(5):1030-1038. PubMed ID: 30623408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
    Uppal SK; Chat VS; Kearns DG; Wu JJ
    J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
    Eichenfield LF; Simpson EL; Papp K; Szepietowski JC; Blauvelt A; Kircik L; Silverberg JI; Siegfried EC; Kuligowski ME; Venturanza ME; Kallender H; Ren H; Paller AS
    Am J Clin Dermatol; 2024 Jul; 25(4):669-683. PubMed ID: 38698175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
    Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
    Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials.
    Igarashi A; Tsuji G; Fukasawa S; Murata R; Yamane S
    J Dermatol; 2024 Nov; 51(11):1404-1413. PubMed ID: 39269202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
    Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
    Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
    J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VTAMA
    Gupta AK; Ravi SP; Vincent K; Abramovits W
    Skinmed; 2022; 20(4):298-300. PubMed ID: 35976021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 Trials.
    Desai SR; Stein Gold L; Cameron MC; Golant A; Lewitt GM; Bruno MJ; Martin G; Brown PM; Rubenstein DS; Butners V; Tallman AM
    Dermatol Ther (Heidelb); 2023 Oct; 13(10):2443-2460. PubMed ID: 37697121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
    Jett JE; McLaughlin M; Lee MS; Parish LC; DuBois J; Raoof TJ; Tabolt G; Wilson T; Somerville MC; DellaMaestra W; Piscitelli SC
    Am J Clin Dermatol; 2022 Jan; 23(1):83-91. PubMed ID: 34713415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials.
    Jett J; McLaughlin M; Wilson T; Somerville M; DellaMaestra W; Rubenstein D; Piscitelli S
    J Drugs Dermatol; 2022 Oct; 21(10):1084-1090. PubMed ID: 36219046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.